EQ vs IMVT vs ARDX vs VKTX vs ABBV

For growth investors, Ardelyx, Inc.

(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -100. 0% for Equillium, Inc. (EQ). AbbVie Inc. (ABBV) offers the better valuation at 94. 8x trailing P/E (16. 0x forward), making it the more compelling value choice. Analysts rate Equillium, Inc. (EQ) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Viking Therapeutics, Inc.

(VKTX) delivered a total return of +370. 6%, compared to -54. 2% for Equillium, Inc. (EQ). Over 10 years, the gap is even starker: VKTX returned +22. 0% versus EQ's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 1118% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ardelyx, Inc.

(ARDX) is pulling ahead at 22. 1% versus -100. 0% for Equillium, Inc. (EQ). On earnings-per-share growth, the picture is similar: AbbVie Inc. grew EPS -0. 8% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -15. 1% for Ardelyx, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -10. 1% for ARDX. At the gross margin level — before operating expenses — ARDX leads at 89. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VKTX: 227.

2% to $93. 60.

In this comparison, ABBV (2.

9% yield) pays a dividend. EQ, IMVT, ARDX, VKTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, VKTX: +22. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EQ is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; VKTX is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock. ABBV pays a dividend while EQ, IMVT, ARDX, VKTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.